VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds


Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Go
Feedback
You are here : IndiaNotes >> Research & Analysis >> Companies >> Sun Pharmaceutical Industries Ltd. >> Research

Sun Pharma in Q1, misses analysts estimates

SMC | 17 Aug, 2017  | Follow Author | Add to my Favourites 
  • Rate this article
    (Average Rating 0.0 Based on 0 ratings)


Highlights of Q1 consolidated financials


- Sales / Income from operations at Rs. 6,167 crores, de-growth of 23% over same quarter last year.


- India sales at Rs. 1,761 crores, down by 5% over Q1 last year.


- US finished dosage sales at US$ 351 million down by 42% over Q1 last year. US sales for Q1 last included the benefit of the 180-day exclusivity for Imatinib which expired in July-2016.


- Emerging Markets sales at US$ 168 million up by 9% over Q1 last year.


- Rest of World sales at US$ 115 million, growth of 37% over Q1 last year.


- R&D investments at Rs. 522 crores (8.5% of sales) compared to Rs. 531 crores (6.6% of sales) for Q1FY17.


- EBITDA at Rs. 297.13 crores.


- Net profit for the quarter was adversely impacted by settlements with certain plaintiffs related to the Modafinil antitrust litigation in the US, with the settlement amounting to Rs 788.72 crores. Excluding the Modafinil settlement, adjusted net profit for Q1FY18 was at Rs. 466 crores, down 79% over Q1 last year, with resulting adjusted net profit margin of 8.5%. Net profit for Q1 last year included the benefit of the 180-day exclusivity for Imatinib which expired in July-2016.


  Read full report Click here to read the full report

logo
BSE
543.00 -1.75
(-0.32%)
NSE
544.75 +0.00
(0.00%)
Read More
About SMC
SMC Research, founded in 1990, is India’s leading share and stock broker, provides a wide range of financial services and investment solutions. A blend of extensive experience, diverse talent and client focus has made us the 4th largest broking house in India(Source: Dun and Bradstreet, 2008). Over the years, SMC has expanded its operations domestically as well as internationally. Existing network includes regional offices at Mumbai, Kolkata, Chennai, Cochin, Ahmedabad, Jaipur, Hyderabad, Bangalore plus a growing network of 2100+ offices spread across 425 cities/towns in India.


For more information please write in to [email protected]

 
Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.



Technical Calls

What are technical calls?

Other Articles


Have a question?